UCBJY - Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals Analyst Asserts | Benzinga
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and a price target of $76.
The analysts Serge Belanger and Rohit Bhasin note the company's lead product developing sonelokimab (SLK), a dual IL-17A/-17F inhibitor nanobody for chronic dermatological ailments like hidradenitis suppurativa (HS) and psoriasis (PsO), outshining established biologics in terms of efficacy.
The analysts expound that SLK has positioned itself as a potential best-in-class treatment, boasting remarkable efficacy that surpasses that of well-known biologics.
The differentiation comes through its innovative approach of concurrently ...